Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study

Overview

Journal J ASEAN Fed Endocr Soc

Specialty Endocrinology

Date 2024 Dec 2

PMID 39620193

Authors

Nemencio Nicodemus Jr

Nerissa Ang-Golangco

Grace Aquitania

Gregory Joseph Ryan Ardena

Oliver Allan Dampil

Richard Elwyn Fernando

Nicole-Therese Flor

Sjoberg Kho

Roberto Mirasol

Araceli Panelo

Francis Pasaporte

Mercerose Puno-Rocamora

Ahsan Shoeb

Marsha Tolentino

Affiliations

Soon will be listed here.

Abstract

Objective: Blood glucose levels of the majority of Filipino patients with type 2 diabetes (T2D) remain uncontrolled. Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of the long-acting basal insulin degludec and the rapidacting prandial insulin aspart. The real-world ARISE (A Ryzodeg Initiation and Switch Effectiveness) study investigated clinical outcomes across six countries in people with T2D who initiated IDegAsp. This publication presents the clinical outcomes of the Filipino cohort from a subgroup analysis of the ARISE study.

Methodology: This 26-week, open-label, non-interventional study examined outcomes in adults with T2D initiating or switching to IDegAsp (N=185) from other antidiabetic treatments per local clinical guidance.

Results: Compared with the baseline, there was a significant improvement in glycated hemoglobin at the end of the study (EOS) (estimated difference [ED] -1.4% [95% confidence interval -1.7, -1.1]; <0.0001). Fasting plasma glucose (ED -46.1 mg/dL [-58.2, -34.0]; <0.0001) and body weight (ED -1.0 kg [-2.0, -0.1]; = 0.028) were significantly reduced at EOS compared with baseline. IDegAsp was associated with a decrease in the incidence of self-reported healthcare resource utilization. Adverse events were reported in eight (4.3%) participants.

Conclusion: Initiating or switching to IDegAsp was associated with improved glycemic control, lower body weight, and lower HRU for people with T2D in the Philippines. No new, unexpected AEs were reported.

References

Tan G . Diabetes Care in the Philippines. Ann Glob Health. 2016; 81(6):863-9. DOI: 10.1016/j.aogh.2015.10.004. View

Kalra S, Aamir A, Raza A, Das A, Azad Khan A, Shrestha D . Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015; 19(5):577-96. PMC: 4566336. DOI: 10.4103/2230-8210.163171. View

Alvarenga M, Komatsu W, de Sa J, Chacra A, Dib S . Clinical inertia on insulin treatment intensification in type 2 diabetes mellitus patients of a tertiary public diabetes center with limited pharmacologic armamentarium from an upper-middle income country. Diabetol Metab Syndr. 2018; 10:77. PMC: 6206856. DOI: 10.1186/s13098-018-0382-x. View

Umpierrez G, Skolnik N, Dex T, Traylor L, Chao J, Shaefer C . When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control. Diabetes Obes Metab. 2019; 21(6):1305-1310. PMC: 6594069. DOI: 10.1111/dom.13653. View

Ozcelik S, Celik M, Vural A, Aydin B, Ozcelik M, Gozu H . Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience. Arch Med Sci. 2021; 17(1):1-8. PMC: 7811302. DOI: 10.5114/aoms.2020.93264. View

Ma R, Chan J . Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013; 1281:64-91. PMC: 3708105. DOI: 10.1111/nyas.12098. View

Jimeno C, Sy R, De La Pena P, Cipriano C, Tan R, Panelo A . Direct medical costs of type 2 diabetes mellitus in the Philippines: findings from two hospital databases and physician surveys. BMJ Open. 2021; 11(10):e049737. PMC: 8506878. DOI: 10.1136/bmjopen-2021-049737. View

Reid T, Gao L, Gill J, Stuhr A, Traylor L, Vlajnic A . How much is too much? Outcomes in patients using high-dose insulin glargine. Int J Clin Pract. 2015; 70(1):56-65. PMC: 4738456. DOI: 10.1111/ijcp.12747. View

Khan M, Hashim M, King J, Govender R, Mustafa H, Al Kaabi J . Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020; 10(1):107-111. PMC: 7310804. DOI: 10.2991/jegh.k.191028.001. View

10.

Evans M, Schumm-Draeger P, Vora J, King A . A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011; 13(8):677-84. PMC: 3380549. DOI: 10.1111/j.1463-1326.2011.01395.x. View

11.

Fulcher G, Jarlov H, Piltoft J, Singh K, Liu L, Mohamed M . ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design. Endocrine. 2021; 74(3):530-537. PMC: 8506473. DOI: 10.1007/s12020-021-02887-8. View

12.

Shah A, Kanaya A . Diabetes and associated complications in the South Asian population. Curr Cardiol Rep. 2014; 16(5):476. PMC: 4026332. DOI: 10.1007/s11886-014-0476-5. View

13.

Eala M, Besa J, Mag-Usara R, Arcellana A, Jimeno C . Access to insulin and diabetes care in the Philippines. Lancet Diabetes Endocrinol. 2021; 10(1):16. DOI: 10.1016/S2213-8587(21)00309-0. View

14.

Higuchi M . Access to diabetes care and medicines in the Philippines. Asia Pac J Public Health. 2010; 22(3 Suppl):96S-102S. DOI: 10.1177/1010539510373005. View

15.

Shigiyama F, Liu L, Nordahl H, Suzuki R, Yamamoto Y, Hirose T . A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan. Diabetes Ther. 2021; 12(9):2405-2421. PMC: 8385001. DOI: 10.1007/s13300-021-01117-8. View

16.

Fulcher G, Akhtar S, Al-Jaser S, Medina J, Mohamed M, Nicodemus Jr N . Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries. Adv Ther. 2022; 39(8):3735-3748. PMC: 9244059. DOI: 10.1007/s12325-022-02212-3. View

17.

Rodbard H, Cariou B, Pieber T, Endahl L, Zacho J, Cooper J . Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Diabetes Obes Metab. 2015; 18(3):274-80. PMC: 5066701. DOI: 10.1111/dom.12609. View

18.

Onishi Y, Ono Y, Rabol R, Endahl L, Nakamura S . Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab. 2013; 15(9):826-32. DOI: 10.1111/dom.12097. View

19.

Franek E, Haluzik M, Canecki Varzic S, Sargin M, Macura S, Zacho J . Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes. Diabet Med. 2015; 33(4):497-505. PMC: 5063147. DOI: 10.1111/dme.12982. View

20.

Lambojon K, Chang J, Saeed A, Hayat K, Li P, Jiang M . Prices, Availability and Affordability of Medicines with Value-Added Tax Exemption: A Cross-Sectional Survey in the Philippines. Int J Environ Res Public Health. 2020; 17(14). PMC: 7400398. DOI: 10.3390/ijerph17145242. View